TheranosticTrials.org

Clinical Trial · NCT05835570

Integrin αvβ6-targeted PET in Malignant Tumors

Overview

Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.

Sponsor

Zhongnan Hospital

Contacts

Yong He, MD, PhD (CONTACT)

vincentheyong@163.com

+86-27-67812698

Yong He, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05835570

Drug / Compound

Trivehexin

Isotope(s):
Target(s):
  • αvβ6
Ligand Class: Peptides
Chelator: TRAP

Eligibility

Inclusion

  • No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT;
  • Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer;
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1;

Exclusion

  • Severe liver or renal dysfunction;
  • Pregnant or breastfeeding women;
  • Refusal to participate or request for withdrawing from the clinical study;
  • Other conditions deemed unsuitable for inclusion by investigator.
  • History of other malignant tumors;
  • Claustrophobia or other psychiatric disorders;
  • Known allergy to injection or its excipients;
  • Participation in another clinical trial within 30 days prior to PET/CT scan;